Kent Kresa to Retire from MannKind’s Board of Directors; Steven B. Binder to be Appointed to the Board
14 8월 2024 - 9:00PM
MannKind Corporation (Nasdaq: MNKD), a company
focused on the development and commercialization of innovative
inhaled therapeutic products and devices for patients with
endocrine and orphan lung diseases, announced today that Kent Kresa
has decided to retire from MannKind’s Board of Directors effective
September 30, 2024. In addition, the Board of Directors has
appointed Steven B. Binder to the Board, also effective September
30, 2024.
Kresa, who has served on MannKind’s Board of Directors since
June 2004, was Chairman from 2016 until December 2020. Upon his
retirement from the MannKind Board, Mr. Kresa will continue to be
associated with the company in the capacity of Chairman
Emeritus.
Binder previously served as MannKind’s Chief Financial Officer
from July 2017 until April 2024 and currently serves as Executive
Vice President, Special Projects. Mr. Binder will remain in that
role until he joins the Board of Directors on September 30, 2024,
after which he will no longer be an employee of the Company.
“We are sincerely grateful for two decades of invaluable
leadership that Kent has provided the Board of Directors,”
said James S. Shannon, Chairman of the Board. “We are looking
forward to Steve joining the Board as he was instrumental in
providing financial stewardship to MannKind during his tenure
and helped bring MannKind into its current era with multiple
revenue streams and healthy pipeline progression.”
With the addition of Binder, there will remain nine total
members of the MannKind Board of Directors.
About MannKindMannKind Corporation (Nasdaq:
MNKD) focuses on the development and commercialization of
innovative inhaled therapeutic products and devices to address
serious unmet medical needs for those living with endocrine and
orphan lung diseases.
We are committed to using our formulation capabilities and
device engineering prowess to lessen the burden of diseases such as
diabetes, nontuberculous mycobacterial (NTM) lung disease,
pulmonary fibrosis, and pulmonary hypertension. Our signature
technologies – dry-powder formulations and inhalation devices –
offer rapid and convenient delivery of medicines to the deep lung
where they can exert an effect locally or enter the systemic
circulation, depending on the target indication.
With a passionate team of Mannitarians collaborating nationwide,
we are on a mission to give people control of their health and the
freedom to live life.
Please visit mannkindcorp.com to learn more, and follow us on
LinkedIn, Facebook, X or Instagram.
MANNKIND is a registered trademark of MannKind Corporation.
For MannKind:
Christie Iacangelo
Corporate Communications
(818) 292-3500
Email: media@mnkd.com
Investor Relations
(818) 661-5000
Email: ir@mnkd.com
MannKind (NASDAQ:MNKD)
과거 데이터 주식 차트
부터 7월(7) 2024 으로 8월(8) 2024
MannKind (NASDAQ:MNKD)
과거 데이터 주식 차트
부터 8월(8) 2023 으로 8월(8) 2024